Kristin Brooks04.08.21
Imvax, Inc., a developer of immunotherapy for Glioblastoma (GBM) and other cancers, has appointed Sean Hemingway as Chief Operating Officer.
Hemingway will lead the expansion of Imvax's new manufacturing facility at The Curtis and support IT and facilities management functions. He will also oversee the manufacturing and supply organization, while building out Imvax's cell therapy platform.
"Sean brings invaluable knowledge of project management, manufacturing operations, and network strategy to Imvax," said John Furey, CEO of Imvax. "His experience will streamline operations, allowing us to refine our antigen-agnostic and proprietary methodology approach to treating tumors with unmet medical needs, helping hundreds of patients across the globe."
Hemingway has more than 25 years of experience in biological manufacturing and supply chain. He has held both domestic and international positions and played key roles in several corporate integrations. Prior to joining the company, he was senior vice president and global head of the BioLife Plasma Services Business Unit at Takeda. He also held leadership positions at Pfizer, Genzyme, and Baxalta.
"Sean brings invaluable knowledge of project management, manufacturing operations, and network strategy to Imvax," said John Furey, CEO of Imvax. "His experience will streamline operations, allowing us to refine our antigen-agnostic and proprietary methodology approach to treating tumors with unmet medical needs, helping hundreds of patients across the globe."
Hemingway has more than 25 years of experience in biological manufacturing and supply chain. He has held both domestic and international positions and played key roles in several corporate integrations. Prior to joining the company, he was senior vice president and global head of the BioLife Plasma Services Business Unit at Takeda. He also held leadership positions at Pfizer, Genzyme, and Baxalta.
